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Introduction: Patients with end-stage kidney disease (ESKD) exhibit anemia, chronic kidney disease‒
mineral bone disorder (CKD–MBD), and cardiovascular disease. The REN-001 and REN-002 phase II,
multicenter, randomized studies examined safety, tolerability, and effects of sotatercept, an ActRIIA-IgG1
fusion protein trap, on hemoglobin concentration; REN-001 also explored effects on bone mineral density
(BMD) and abdominal aortic vascular calcification.
Methods: Forty-three patients were treated in REN-001 (dose range: sotatercept 0.3‒0.7 mg/kg or placebo
subcutaneously [s.c.] for 200 days) and 50 in REN-002 (dose range: 0.1‒0.4 mg/kg i.v. and 0.13‒0.5 mg/kg
s.c. for 99 days).
Results: In REN-001, frequency of achieving target hemoglobin response (>10 g/dl [6.21 mmol/l]) with
sotatercept was dose-related and greater than placebo (0.3 mg/kg: 33.3%; 0.5 mg/kg: 62.5%; 0.7 mg/kg:
77.8%; 0.7 mg/kg [doses 1 and 2]/0.4 mg/kg [doses 3‒15]: 33.3%; placebo: 27.3%). REN-002 hemoglobin
findings were similar (i.v.: 16.7%57.1%; s.c.: 11.1%‒42.9%). Dose-related achievement of $2% increase in
femoral neck cortical BMD was seen among only REN-001 patients receiving sotatercept (0.3‒0.7 mg/kg:
20.0%‒57.1%; placebo: 0.0%). Abdominal aortic vascular calcification was slowed in a dose-related
manner, with a #15% increase in Agatston score achieved by more REN-001 sotatercept versus placebo
patients (60%‒100% vs. 16.7%). The most common adverse events during treatment were hypertension,
muscle spasm, headache, arteriovenous fistula site complication, and influenza observed in both treat-
ment and placebo groups.
Conclusion: In patients with ESKD, sotatercept exhibited a favorable safety profile and was associated with
trends in dose-related slowing of vascular calcification. Less-consistent trends in improved hemoglobin
concentration and BMD were observed.
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P atients with ESKD experience anemia associatedwith decreased renal biosynthesis of erythropoietin,
iron deficiency, and elevated hepcidin.1–4 Several
erythropoiesis-stimulating agents (ESAs) increase hemo-
globin (Hb) levels in ESKD patients yet pose safety chal-
lenges, without modifying cardiovascular risk.5–9
Sotatercept (ACE-011), an activin receptor type IIA
(ActRIIA)-IgG1 fusion protein trap, binds with high af-
finity to activin A and other members of the transform-
ing growth factor-b (TGF-b) superfamily10 and acts on
late-stage erythropoiesis to increase production of mature
erythrocytes.11,12 Dose-dependent effects on Hb were
seen with sotatercept in healthy volunteers.13,14
In addition, ESKD is associated with CKD–MBD,
which is associated with cardiovascular disease, renal
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osteodystrophy with low bone volume, and disordered
mineral metabolism.15–18 In CKD, activin receptors are
stimulated in skeletal, vascular, and heart tissues,
implicating a possible role for sotatercept in amelio-
rating CKD-related cardiovascular disease and osteo-
dystrophy.19 A murine analog of sotatercept increased
bone formation, leading to increased bone density and
strength and decreased atherosclerotic vascular calci-
fication in a preclinical CKD model.10,20,21
We report findings from 2 phase II, multicenter,
randomized studies (REN-001 and REN-002) of ESKD
patients undergoing hemodialysis and with anemia.
Both studies evaluated the multiple-dose safety, phar-
macokinetic, and pharmacodynamic effects of sota-
tercept on serum Hb concentration. REN-001 also
explored effects on BMD and vascular calcification.
REN-001 was placebo-controlled and evaluated sota-
tercept for the correction of anemia after ESA washout;
REN-002 was an open-label study that evaluated Hb
maintenance in ESKD patients after switching from a
prior ESA. These studies shared an objective of
exploring dosing strategies that would safely impact
pharmacodynamic parameters, primarily Hb, and
might translate into clinical benefit in larger clinical
trials.
METHODS
Patients
For either study, patients had to be aged $18 years with
ESKD, on hemodialysis ($3 hours of high-flux hemodi-
alysis at each session for $12 weeks before screening),
and on a stable ESA dose for $6 weeks before screening.
Proven ESA responsiveness was required (mean Hb
values: 10‒12 g/dl [6.21–7.45 mmol/l]). Patients were
excluded if they had anemia due to non-renal causes,
were receiving peritoneal dialysis, had systemic hemato-
logic disease, were medically unstable, or had uncon-
trolled diabetes mellitus (HbA1c >9%), hypertension
(home systolic blood pressure [BP]>160 mm Hg, or home
diastolic BP >90 mm Hg), or heart failure (New York
Heart Association classification $3).
Study Design
ACE-011-REN-001 (REN-001; NCT01146574) Part 1 was
a double-blind, placebo-controlled study evaluating
pharmacokinetics, dialysis clearance, and safety of
sotatercept following a single s.c. dose (0.1 mg/kg).
REN-001 Part 2 was a randomized, single-blind, pla-
cebo-controlled study of s.c. sotatercept administration
in doses ranging from 0.3 to 0.7 mg/kg, evaluating for
the correction of anemia after ESA washout. Patients
could receive treatment over 200 days if they did not
require rescue or if the Hb threshold was not exceeded;
the sotatercept 0.3, 0.5, and 0.7 mg/kg dose groups
received up to 8 doses, given every 28 days, and the
0.7/0.4 mg/kg dose group received up to 15 doses
(doses 1 and 2: 0.7 mg/kg; doses 3‒15: 0.4 mg/kg),
given every 14 days.
ACE-011 REN-002 (REN-002; NCT01999582) was an
open-label, randomized study evaluating i.v. and s.c.
sotatercept administration routes in doses ranging from
0.1 to 0.4 mg/kg (i.v.) and 0.13 to 0.5 mg/kg (s.c.)
evaluating Hb maintenance after switching from a prior
ESA. Patients could receive up to 8 doses given every
14 days over 99 days.
Study designs for REN-001 and REN-002 are illus-
trated in Figure 1. In both studies, if Hb fell below 9 g/
dl (5.59 mmol/l), patients received rescue ESA treat-
ment and discontinued sotatercept dosing. In REN-002,
dose escalation in increments of 0.1 mg/kg was
permitted in dose group 3 if an Hb reduction $1 g/dl
(0.62 mmol/l) occurred or absolute Hb was <10 g/dl
(6.21 mmol/l). Both studies followed patients for 112
days after their last sotatercept dose.
Dosing Rules Based on Hb Concentration
Sotatercept doses were delayed if absolute Hb con-
centration exceeded defined thresholds (REN-001: $11
g/dl [6.83–8.07 mmol/l]; failed to decrease to <11 g/dl
[6.83 mmol/l] by day 36 [day 29 þ 7 days ¼ window
for groups 1‒3] or by day 19 [day 15 þ 4 days for
group 3a]; REN-002: >12 to <13 g/dl [7.45–8.07 mmol/
l]). Doses were also delayed if the Hb rate of rise
was $1 g/dl (0.62 mmol/l) at any time since the last
dose (REN-002: over 14 days). In REN-001, a half-dose
reduction of sotatercept occurred when Hb was <11 g/
dl (6.83 mmol/l), but the rate of rise was >2 g/dl (1.24
mmol/l) (over 28 days, groups 1‒3) or >1 g/dl (0.62
mmol/l) (over 14 days, group 3a). Sotatercept was re-
dosed when the Hb concentration returned to <11 g/
dl (6.83 mmol/l) (REN-001: resumed at half the previous
dose; REN-002: resumed at the full assigned dose).
Sotatercept was discontinued if the absolute Hb
was $13 g/dl (8.07 mmol/l) (REN-002 only; if Hb
was <14 g/dl [8.69 mmol/l], it could be reconfirmed
within 7 days) or Hb was >12 g/dl (7.45 mmol/l) to <13
g/dl (8.07 mmol/l) for 2 consecutive weeks (REN-001
only).
Dosing Rules Based on Home BP
In addition to recording predialysis and postdialysis
seated BP, home BP monitoring was used to evaluate
safety because of a patient who experienced progres-
sive hypertension due to a rapid rise in her Hb level in
a study of healthy postmenopausal women. Patients
were assigned a home BP monitor and trained in its use.
Sotatercept dosing could be modified, interrupted, or
discontinued based on BP increases. Sotatercept was
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Figure 1. Study designs for REN-001 (a) and REN-002 (b). *If hemoglobin (Hb) levels are>11 g/dl (6.83mmol/l) and have not returned to<11 g/dl by day 36
(window is day 29 þ 7 days) of a dosing cycle, sotatercept/placebo doses 2 to 8 may be delayed until Hb is <11 g/dl. Patients will be dosed when Hb
is <11 g/dl. †If Hb levels are >11 g/dl and have not returned to <11 g/dl by day 19 (window is day 15þ 4 days) of a dosing cycle, sotatercept/placebo
doses 2 to 15 may be delayed until Hb is<11 g/dl. Patient will be dosed when Hb is<11 g/dl. BMD, bone mineral density; ESA, erythropoiesis-stimulating
agent; ESKD, end-stage kidney disease; PK, pharmacokinetic; qCT, quantitative computed tomography; s.c., subcutaneous.
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discontinued if mean systolic BP was >200 mm Hg or
mean diastolic BP was >110 mm Hg at any time (REN-
002 only), or if mean pre-dose home systolic BP was
>160 mm Hg and there was a >20 mm Hg systolic BP
increase or a >10 mm Hg diastolic BP increase from
baseline. In response to increased BP, dialysis and/or
antihypertensive medications could be modified at the
investigator’s discretion, with mean home BP reas-
sessed before the next dosing visit. In REN-002, post-
dose home BP values were evaluated for 2 days
following each dose.
Quantitative Computed Tomography
A quantitative computed tomography (qCT) scan of the
hip, lumbar spine, and abdominal aorta was obtained at
baseline and after the 225-day treatment phase.
Trabecular volumetric BMD (mg/cm3) was determined
for 2 vertebrae within L1-4 (typically L1-2); left
proximal femurs were analyzed for volumetric BMD of
the cortical, trabecular, and integral bone compart-
ments of the total hip, femoral neck, and trochanteric
regions using Mindways QCT PRO software (version
4.0; Mindways Software, Austin, TX).
All study sites were provided quality assurance (QA)
and CT calibration (Mindways Model 3, Mindways
Software) phantoms to standardize qCT results from the
multiple CT scanners. Each CT instrument calibration
was collected before scanning using the QA and cali-
bration phantoms. Study sites continued acquiring QA
scans once weekly and before each scan to enable
longitudinal performance monitoring of all CT in-
struments. These data were incorporated into the qCT
analysis using QCT PRO software to account for intra-
scanner calibration changes as needed.
Abdominal aorta vascular calcification was assessed
using software that semi-automatically segmented the
area and volume of calcifications within the region
adjacent to the top of L1 through the bottom of L4 (Alice
Software, PAREXEL Informatics, Waltham, MA). Num-
ber and location of slices measured were maintained
across visits per patient. Agatston scores, aortic calcifi-
cation volume, and square root–transformed calcium
volume scores were determined, as described else-
where.22,23 All image quality control and blinded ana-
lyses were performed centrally by an imaging core
laboratory (PAREXEL International Corp., Waltham,
MA). Results are based on all available data from patients
with paired qCT assessments at baseline and day 225.
Assessments and Statistical Analysis
REN-001
Primary endpoints for Part 2 were sotatercept serum
pharmacokinetic parameters. Efficacy measures related
to Hb were secondary endpoints and were analyzed
using descriptive statistics. Efficacy analyses were
conducted using the full analysis set (i.e., all random-
ized patients who received $1 dose of study treatment
and had $1 postrandomization observation and a
baseline value [only for those endpoints requiring
baseline for analysis]). Placebo arms were combined for
all efficacy and safety analyses. Efficacy endpoints
included proportions of patients achieving an absolute
Hb concentration >10 g/dl (6.21 mmol/l) at any time
before rescue during the treatment period, and those
requiring rescue therapy during the treatment period.
Time to target Hb concentration and time to receiving
rescue treatment were summarized. Exploratory end-
points based on qCT included proportions of patients
with a >2% increase from baseline in BMD assessments
of femoral neck, lumbar spine, and hip, and change
from baseline in Agatston scores for abdominal aorta
vascular calcification. No formal hypothesis testing or
treatment comparison was performed for the explor-
atory endpoints.
REN-002
Primary endpoints were sotatercept serum pharmacoki-
netic parameters. Secondary endpoints included pro-
portions of patients maintaining a mean Hb
concentration of $10 to #12 g/dl (6.21–7.45 mmol/l)
between days 98 and 113 and requiring rescue therapy
(Hb <9 g/dl [5.59 mmol/l]) during the treatment period.
Efficacy measures were analyzed using descriptive sta-
tistics among the full analysis set; safety was examined in
the safety population (i.e., all randomized patients who
received $1 dose of study treatment).
RESULTS
Patient Disposition
REN-001
In Part 1, a total of 7 patients from 4 US sites were
enrolled (placebo: n ¼ 1; sotatercept 0.1 mg/kg s.c.:
n ¼ 6). In Part 2, a total of 43 patients from 13 US sites
were enrolled and received $1 dose of study medica-
tion by s.c. injection (placebo: n ¼ 11; sotatercept 0.3
mg/kg: n ¼ 9 [group 1]; 0.5 mg/kg: n ¼ 8 [group 2]; 0.7
mg/kg: n ¼ 9 [group 3]; 0.7/0.4 mg/kg: n ¼ 6 [group
3a]). In the placebo group, 1 of 11 (9.1%) patients
completed the study treatment (i.e., received assigned
study treatment throughout the 200-day treatment
phase); among the treatment groups, the sotatercept 0.3
mg/kg group had the lowest proportion of completers
(2 of 9 patients [22.2%]), and the sotatercept 0.7 mg/kg
group had the highest proportion of completers (4 of 9
patients [44.4%]). Rescue ESA administration due to
Hb concentration <9 g/dl (5.59 mmol/l) was the pri-
mary reason for discontinuation across all treatment
groups (Figure 2).
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REN-002
Fifty patients from 16 European Union sites were ran-
domized and received $1 dose of sotatercept (i.v. doses
0.1 mg/kg, n ¼ 7; 0.2 mg/kg, n ¼ 9; 0.1‒0.4 mg/kg,
n ¼ 12; s.c. doses 0.13 mg/kg, n ¼ 7; 0.26 mg/kg, n ¼
9; 0.4‒0.5 mg/kg, n ¼ 6). Thirty (60%) patients
completed study treatment throughout the 99-day
treatment phase; 20 (40%) patients discontinued.
Among those receiving sotatercept, the s.c. 0.4 to 0.5
mg/kg dose group had the lowest proportion of com-
pleters (3 of 6 patients [50.0%]), and the i.v. 0.1 to 0.4
mg/kg dose group had the highest proportion of
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N=50
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0.26 mg/kg s.c.
n=9
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Completed study
n=4
Completed study 
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n=3
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Other 1
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Withdrew consent 1
Other 1
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n=2
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Withdrew consent 1
Other 1
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n=7
Sotatercept
0.1 mg/kg i.v.
n=7
Sotatercept
0.13 mg/kg s.c.
n=7
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0.2 mg/kg i.v.
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Other 1
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n=6
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N=43
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n=9
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n=6
Discontinued  study drug 
n=7
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Administered rescue therapy 6
Simultaneous early 1
termination from study 
during treatment phase
Discontinued  study drug 
n=5
Reasons:
Systolic BP* 1
Administered rescue therapy 4
Discontinued  study drug 
n=5
Reasons:
Systolic BP* 1
Administered rescue therapy 4
Adverse event 1
Discontinued  study drug 
n=4
Reasons:
Administered rescue therapy 3
Adverse event 1
Discontinued study drug 
n=10
Reasons:
Administered rescue therapy 8
Adverse event 1
Simultaneous early 2
termination from study 
during treatment phase
Discontinued study†
n=2
Reasons:
Withdrew consent 1
Kidney transplant 1
Discontinued study†
n=2
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Withdrew consent 2
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n=1
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Withdrew consent 1
Discontinued study†
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Withdrew consent 1
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Kidney transplant 1
Other 3
Completed treatment phase
n=7
Completed treatment phase
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n=6
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n=8
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n=5
Completed study drug
n=2
Completed study drug
n=1
Completed study drug
n=3
Completed study drug
n=4
Completed study drug
n=2
REN-001 Part 2a
Figure 2. Patient disposition. Disposition of patients is illustrated for REN-001 Part 2 (a) and for REN-002 (b). Reasons for early discontinuation of
treatment are noted; patients may have had more than 1 reason for discontinuation of study drug. *Home systolic blood pressure (BP) of >160
mm Hg plus a change from baseline of systolic BP >20 mm Hg or a diastolic BP >10 mm Hg. †Early termination from the study during the
treatment phase. ‡A 76-year-old female receiving placebo died on study day 148. Cause of death was cardiomyopathy. §A 70-year-old male with
a history of hypertension, myocardial infarction, and mitral valve incompetence died within 115 days of the last dose (subcutaneous [s.c.]
sotatercept 0.4‒0.5 mg/kg). Cause of death (severe cardiac failure) was not considered by the investigator to be treatment-related.
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completers (10 of 12 patients [83.3%]). The most com-
mon reasons for discontinuation were lack of efficacy
(n ¼ 5) and adverse event (AE; n ¼ 4) across all the
treatment groups; 8 patients discontinued for other
reasons unrelated to safety (Figure 2).
Dialysis Prescription
Patients in both studies were on a fixed dialysis protocol,
and there were no changes in dialysis prescriptions
during the study period. Baseline demographics, dialysis
treatment history, and concomitant phosphate-binder
use are reported in Supplementary Tables S1 and S2.
Primary Endpoint: Pharmacokinetics
REN-001
In the Part 1 noncompartmental pharmacokinetic
analysis, sotatercept 0.1 mg/kg s.c. single dose was
slowly absorbed into systemic circulation (median time
to maximum plasma concentration, approximately 6
days), exhibiting a mean terminal half-life (t1/2,z) of 21.1
days (n ¼ 6; Table 1). Serum sotatercept concentration
showed no changes during dialysis, indicating that the
drug is nondialyzable. In the Part 2 noncompartmental
analysis, sotatercept mean 28-day exposure (area under
the concentration-time curve from 0 to 28 days [AUC0–
28days]) and maximum serum concentration (Cmax)
increased in an approximate dose-proportional manner
from a dose of 0.3 mg/kg to 0.7 mg/kg. The 14-day
dosing regimen, with loading dose in the first month
(dose group 3a), led to increased AUC and Cmax levels
and higher trough concentration (not shown). Sota-
tercept displayed elimination rates across all dose
groups ranging from 20‒32 days.
REN-002
Increases in AUC028days and Cmax were approximately
dose-proportional, from 0.1 to 0.2 mg/kg for the i.v.
sotatercept dosing (Table 1). A dose-dependent increase
in AUC028days and Cmax was not obvious for s.c.
sotatercept dosing from 0.4 to 0.5 mg/kg, likely due to
the small sample size and higher interpatient vari-
ability. Regardless of administration route, sotatercept
displayed elimination rates ranging from 18 to 26 days.
Table 1. PK parametersa of sotatercept in REN-001 and REN-002 (noncompartmental analysis)
PK parameter, mean (CV%)
REN-001 Part 1
Sotatercept dose: 0.1 mg/kg s.c.
n [ 6
Cmax, mg/ml 1.02 (56.4)
Tmax,
a d 6.02 (3.1, 14.0)
AUC0–28days, dmg/ml 20.64 (55.2)
t1/2,z,
b d 21.07 (18.4)
REN-001 Part 2
Sotatercept dose (s.c.)
0.3 mg/kg
n [ 9
0.5 mg/kg
n [ 8
0.7 mg/kg
n [ 9
0.7/0.4 mg/kg
n [ 6
Cmax0‒28days, mg/ml 2.40 (40.0) 3.66 (18.3) 3.97 (41.3) 7.71 (25.6)
Tmax0‒28days,
a d 11.94 (2.0, 14.0) 6.96 (0.02, 14.0) 12.00 (5.0, 16.9) 18.50 (15.0, 21.0)
AUC0‒28days, dmg/ml 50.64 (34.9) 78.03 (17.1) 87.51 (41.9) 126.96 (16.4)
(n ¼ 5)
t1/2,z,
b d 24.31 (13.5)
(n ¼ 8)
32.07 (61.9) 22.16 (31.6) 19.61 (14.8)
REN-002
Sotatercept administration route and dose
i.v.
0.1 mg/kg
n [ 6
i.v.
0.2 mg/kg
n [ 6
i.v.
0.1L0.4 mg/kg
n [ 9
s.c.
0.13 mg/kg
n [ 4
s.c.
0.26 mg/kg
n [ 8
s.c.
0.13L0.5 mg/kg
n [ 4
Cmax0‒28days, mg/ml 3.56 (19.7)
(n ¼ 4)
8.61 (41.3)
(n ¼ 3)
3.50 (61.2)
(n ¼ 5)
3.87 (93.4)
(n ¼ 3)
1.97 (57.4)
(n ¼ 4)
3.16 (24.9)
(n ¼ 2)
Tmax0‒28days,
a d 14.1 (14.0, 16.0)
(n ¼ 4)
14.0 (14.0, 16.0)
(n ¼ 3)
0.169 (0.004, 16.0)
(n ¼ 5)
21.0 (16.2, 28.0)
(n ¼ 3)
18.5 (16.0, 21.0)
(n ¼ 4)
21.0 (21.0, 21.1)
(n ¼ 2)
AUC0‒28days, dmg/ml 38.36 (22.4)
(n ¼ 4)
94.11 (39.5)
(n ¼ 3)
33.17 (26.3)
(n ¼ 5)
41.50 (32.9)
(n ¼ 3)
36.07 (63.3)
(n ¼ 4)
60.50 (24.2)
(n ¼ 2)
t1/2,z,
b d 17.6 (26.3) 21.8 (18.1) 22.5 (23.8) 25.9 (27.6) 21.0 (25.7) 20.4 (26.0)
AUC0‒28days, area under the curve during a 28-day exposure period; Cmax0‒28days, maximum plasma concentration during a 28-day exposure period; CV%, coefficient of variance; PK,
pharmacokinetic; s.c., subcutaneous; t1/2,z, terminal half-life; Tmax0‒28days, time to Cmax during a 28-day exposure period.
aTmax, Tmax0–28days expressed as median (range).
bElimination half-life estimated by noncompartmental method using concentrations after a single dose (REN-001 part 1) and the last dose (REN-001 part 2 and REN-002).
The n reflects the number of randomized patients who underwent PK testing; actual number of patients with data available for each parameter may vary. PK parameters for REN-001 and
REN-002 are based on noncompartmental analysis.
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Secondary Endpoints: Target Hb
REN-001
In dose groups 1‒3 for up to 200 days of treatment, a
general trend toward increase in mean Hb concentration
and mean change from baseline in Hb concentration
over time was observed across treatment groups. No
consistent trend was observed in mean Hb concentration
or mean change from baseline in Hb concentration over
time in dose group 3a. Figure 3a summarizes the pro-
portions of patients achieving predefined target Hb for
REN-001 (Hb >10 g/dl [6.21 mmol/l] any time during
the treatment period). There were no consistent trends
in time to achieve target Hb across the placebo and
sotatercept dose groups (range median time to target, Hb
censored for rescue: 1.0‒18.5 days).
Fewer patients were rescued in the sotatercept 0.5
and 0.7 mg/kg treatment groups compared with the
sotatercept 0.3 mg/kg and placebo groups (Figure 3c).
Because of the small group size, the chance that dif-
ferences between groups existed by chance could not
be excluded. All 6 sotatercept 0.7/0.4 mg/kg patients
required rescue during the treatment period. Mean
time to rescue was longest with sotatercept 0.7 mg/kg
(100.4 days) and 0.7/0.4 mg/kg (117.5 days) and
shortest with placebo (44.8 days).
REN-002
Sixteen (32%) patients maintained predefined target Hb
($10.0 [6.21 mmol/l] and #12.0 g/dl [7.45 mmol/l] for
visits 14‒17) without rescue medication. Proportionately
more patients in s.c. groups 2 (33%) and 3 (50%) met
this criterion, versus i.v. dose groups 2 (11%) and 3
(25%), although the small sample size in each dose group
makes comparisons difficult (Figure 3b).
Overall, during the treatment period, similar pro-
portions of patients used rescue therapy in the i.v. (8 of
28 patients [28.6%]) and s.c. (6 of 22 patients [27.3%])
dose groups. A trend toward lower rescue therapy use
was observed with higher i.v. doses (Figure 3d).
Exploratory Endpoints: Effects on Bone
Endpoints (REN-001)
In 27 patients with paired qCT measurements at base-
line and day 225, there were no consistent trends in the
mean percent changes from baseline in lumbar spine or
total hip BMD. One patient (sotatercept 0.7 mg/kg) had
a $2% increase from baseline in total hip cortical
BMD. No placebo or sotatercept 0.7/0.4 mg/kg patients
had a $2% increase from baseline in femoral neck
cortical BMD; the proportions of patients achieving
a $2% increase from baseline in femoral neck cortical
BMD increased with sotatercept dose (Figure 4). Mean
percent changes from baseline in femoral neck cortical
BMD were 1.2% (placebo), 1.4% (0.3 mg/kg), 1.6%
(0.5 mg/kg), 1.0% (0.7 mg/kg), and 2.4% (0.7/0.4 mg/
kg). Median (minimum, maximum) BMD values and
other bone remodeling outcomes are presented in
Supplementary Table S3.
Change in Vascular Calcification of the
Abdominal Aorta (REN-001)
The highest mean percentage increase from baseline in
Agatston score (48.6%) was observed with placebo
(mean Agatston score: 5216 at day 225) and the smallest
(7.6%) was observed with sotatercept 0.7 mg/kg (mean
Agatston score: 4411 at day 225). Similar results were
observed for volumetric score and square root of
volumetric score. Among patients with paired assess-
ments at baseline and day 225, proportions with
a #15% increase from baseline in Agatston score were
higher in all sotatercept treatment groups versus the
placebo group. All sotatercept 0.7 mg/kg patients had
a#15% increase from baseline in Agatston score at day
225 (Figure 5). Among patients with paired assessments
of volumetric score and square root of volumetric
score, the smallest mean percentage increases from
baseline (9.5% and 4.6%, respectively) were observed
with sotatercept 0.7 mg/kg treatment (Figure 5).
Among patients with assessments of square root of
volumetric score at baseline and day 225, the propor-
tion with a #2.5-mm increase from baseline in square
root of volume score was higher with sotatercept 0.5
mg/kg (5 of 5) and 0.7 mg/kg (6 of 8) versus placebo
(4 of 6). Median (minimum, maximum) Agatston scores
are presented in Supplementary Table S3.
Safety
REN-001
No dose-related increase was observed in incidence of
treatment-emergent AEs (TEAEs) with sotatercept
treatment. The most common TEAEs in these patients
were hypertension, nausea, and fatigue (Table 2). Two
deaths occurred in the placebo group: One female
died on study day 148 due to cardiomyopathy and
1 male died on day 186 due to worsening coronary
artery disease. There were no deaths in the sotatercept
treatment groups. No association between TEAE
occurrence and sotatercept mean AUC0–28days or Cmax
was observed.
Serious AEs (SAEs) were reported in 13 patients
(Table 2). The SAEs reported by >1 sotatercept patient
were gastroenteritis and hypertensive crisis. Two SAEs
were considered treatment-related (atrial fibrillation:
n ¼ 1 [sotatercept 0.3 mg/kg]; anemia [reported by the
investigator as an SAE instead of lack of efficacy, per
protocol]: n ¼ 1 [sotatercept 0.3 mg/kg]).
BP assessments at clinic visits or periodic inter-
dialytic ambulatory home monitoring showed no dose-
related trends versus placebo. Hypertension events
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Figure 3. Hemoglobin endpoints are shown for REN-001 (a) and REN-002 (b), and rescue treatment is shown for REN-001 (c) and REN-002 (d). For
REN-001, the target Hb was >10 g/dl (6.21 mmol/l) at any time before rescue during the treatment period; for REN-002, the target Hb was $10
(6.21 mmol/l) to#12 g/dl (7.45 mmol/l) at any time before rescue between days 98 and 115. If Hb was <9 g/dl (5.59 mmol/l), or at the discretion of
the investigator if deemed necessary for the safety and well-being of the patient, a blood transfusion or erythropoietin-stimulating agent therapy
was given. Because of the small group size, the chance that differences between groups existed because of chance could not be excluded.
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were the most frequently reported TEAEs in sota-
tercept patients. All hypertension TEAEs were mild/
moderate in severity; none were considered treatment-
related.
One patient (sotatercept 0.7 mg/kg) had at least 1 Hb
measurement >12 g/dl (7.45 mmol/l), and 1 patient
(sotatercept 0.5 mg/kg) had a rise in Hb concentration
>2 g/dl (1.24 mmol/l) during any 4-week treatment
period. Patients with these Hb increases did not
experience AEs of hypertension or increased BP.
No persistent or dose-related changes were noted in
laboratory parameters (including chemistries, lipids,
HbA1c, sex steroids, and non‒red blood cell–related
hematology parameters) or electrocardiographic
parameters.
REN-002
Forty-one patients experienced $1 TEAE; <10% had
treatment-related AEs or a TEAE leading to treatment
discontinuation. Approximately one-fourth experi-
enced SAEs (Table 2). The most commonly reported
TEAEs were hypertension, muscle spasms, headache,
arteriovenous fistula site complication, and influenza
(Table 2). No association between TEAE occurrence and
sotatercept AUC0–28days or Cmax was observed.
Although 40% of patients had Hb >12 g/dl (7.45
mmol/l) after the first dose, and 44% had a change
from baseline in Hb >1.0 g/dl (0.62 mmol/l), neither
occurrence appeared to be dose-related; 8% had Hb
>13 g/dl (8.07 mmol/l) without discontinuation of
study medication, and 2% had Hb >13 g/dl
(8.07 mmol/l), leading to treatment discontinuation.
These increases in Hb >12 g/dl (7.45 mmol/l) or
>13 g/dl (8.07 mmol/l) were not accompanied by
hypertension or increased BP AEs. Mean changes
from baseline in home systolic and diastolic BP
values across all patients showed considerable vari-
ability within and across dose groups, with no clear
trend.
One death occurred. A 70-year-old male with a
history of hypertension, myocardial infarction, and
mitral valve incompetence died within 115 days of the
last dose (s.c. sotatercept 0.4‒0.5 mg/kg). Cause of
death (severe cardiac failure) was not considered by the
investigator to be treatment-related.
Anti-Sotatercept Antibodies
REN-001
Anti-sotatercept antibodies were detected in 3 patients
during Part 2 (Supplementary Table S4). One patient
(sotatercept 0.7 mg/kg) tested positive on day 1 of dose
cycle 1 and remained positive through day 309 and at 3
unscheduled follow-up visits. One patient (sotatercept
0.7/0.4 mg/kg) tested positive on day 1 of dose cycle 2
and then tested negative through day 112; another
receiving the same dose tested positive on day 1 of dose
cycle 2 and through day 15. No TEAEs of hypersen-
sitivity were reported in any patient positive for anti-
sotatercept antibodies. Anti-sotatercept antibodies
were not factors in the decisions related to repeated
dosing. The anti-sotatercept antibodies did not have an
impact on safety or efficacy, and the Hb response did
not differ in these patients.
REN-002
Anti-sotatercept antibodies were detected in 7 patients
(Supplementary Table S4); among these, 5 were in the
i.v. dosing groups and 2 were in the s.c. sotatercept 0.13
mg/kg dosing group. In all antidrug antibody-positive
patients, the first confirmed positive sample was
observed z28 days after the first dose. Antidrug anti-
body titer tended to decrease over time, and most anti-
drug antibody-positive patients were antibody-negative
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Figure 4. Patients with a $2% increase in femoral neck cortical bone mineral density in REN-001. Percentages are based on the number of
patients with quantitative computed tomography of femoral neck cortical bone mineral density at baseline and day 225.
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at study end (6 of 7 patients [85.7%]). Antidrug antibody
positivity was not related to hypersensitivity AEs or
other safety concerns.
DISCUSSION
Sotatercept, a ligand trap based on the ActRIIA re-
ceptor for selected proteins of the TGF-b superfamily,
including activin A,10 was originally conceived as a
potential treatment for CKD-related anemia because of
effects on late-stage erythropoiesis observed in pre-
clinical models24 and phase I healthy volunteers.13,14
However, preclinical models demonstrated that the
ActRIIA receptor is activated in skeletal, vascular, and
heart tissue in CKD.19 Therefore, in REN-001, we also
explored the impact of sotatercept on bone and
vascular calcification endpoints. Targeting ActRIIA
activity with sotatercept treatment in ESKD patients in
two phase 2 studies demonstrated an acceptable safety
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Figure 5. The proportion of patients with a#15% increase in vascular calcification of the abdominal aorta by the Agatston score in REN-001 are
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profile and dose-related slowing of vascular calcifica-
tion progression, consistent with previously reported
results in CKD-MBD models using sotatercept’s murine
analog RAP-011.19,20 Improvements were seen in serum
Hb concentration and BMD endpoints, although less
consistently.
In both studies, sotatercept was nondialyzable and
was eliminated slowly, regardless of administration
route. Sotatercept demonstrated an acceptable safety
profile and was well tolerated up to 225 days (up to
eight 28-day or fifteen 14-day dose cycles). Across
both studies, no increase in TEAE incidence was
observed with sotatercept related to dose or admin-
istration route. TEAE occurrence was not associated
with sotatercept mean AUC0–28days or Cmax. Inter-
dialytic ambulatory home BP monitoring, repeated at
regular intervals, did not reveal dose-dependent
changes over time. A higher proportion of all REN-
001 sotatercept treatment groups achieved the
target Hb increase versus the placebo group; Hb
response was dose-related when doses were given
monthly. This dose effect was lost with administra-
tion every 2 weeks. REN-002 Hb findings were
similar, with generally better responses seen among
the s.c. versus i.v. dose groups. No increase in Hb
response or maintenance of Hb response was
apparent with sotatercept when given in higher and/
or more frequent doses, suggesting that sotatercept’s
Hb-stimulatory effect may be limited in ESKD
patients.
REN-001 results from the placebo group were as
expected for CKD-MBD, with increasing trabecular
bone (e.g., increase in lumbar spine BMD), decreasing
cortical BMD (e.g., decrease in femoral neck cortical
BMD), and progressive vascular calcification.15–17
Sotatercept demonstrated a $2% increase from base-
line in femoral neck cortical BMD in a dose-dependent
manner when administered monthly; no treatment
Table 2. Overview of TEAEs in patients receiving sotatercept in REN-001 and REN-002
Patients, n (%)
Placebo
n [ 11
REN-001
All sotatercept
N [ 32
Sotatercept dose (s.c.)
0.3 mg/kg
n [ 9
0.5 mg/kg
n [ 8
0.7 mg/kg
n [ 9
0.7/0.4 mg/kg
n [ 6
Any TEAE 7 (63.6) 8 (88.9) 6 (75.0) 8 (88.9) 4 (66.7) 26 (81.3)
TEAE related to study drug 3 (27.3) 2 (22.2) 0 (0.0) 3 (33.3) 1 (16.7) 6 (18.8)
Serious TEAE 2 (18.2) 4 (44.4) 0 (0.0) 4 (44.4) 1 (16.7) 9 (28.1)
Any TEAE leading to discontinuation 1 (9.1) 0 (0.0) 0 (0.0) 2 (22.2) 1 (16.7) 3 (9.4)
Death 2a (18.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
TEAEs in $3 patients in any treatment group
Hypertension 1 (9.1) 4 (44.4) 0 (0.0) 4 (44.4) 0 (0.0) 8 (25.0)
Nausea 1 (9.1) 1 (11.1) 1 (12.5) 4 (44.4) 0 (0.0) 6 (18.8)
Fatigue 2 (18.2) 2 (22.2) 0 (0.0) 1 (11.1) 2 (33.3) 5 (15.6)
REN-002
All sotatercept
N [ 50
Sotatercept administration route and dose
i.v.
1.1 mg/kg
n [ 7
i.v.
0.2 mg/kg
n [ 9
i.v.
0.1--0.4 mg/kg
n [ 12
s.c.
0.13 mg/kg
n [ 7
s.c.
0.26 mg/kg
n [ 9
s.c.
0.4--0.5 mg/kg
n [ 6
Any TEAE 7 (100.0) 9 (100.0) 10 (83.3) 3 (42.9) 6 (66.7) 6 (100.0) 41 (82.0)
TEAE related to study drug 1 (14.3) 1 (11.1) 0 (0.0) 1 (14.3) 0 (0.0) 1 (16.7) 4 (8.0)
Serious TEAE 3 (42.9) 3 (33.3) 3 (25.0) 0 (0.0) 1 (11.1) 3 (50.0) 13 (26.0)
Any TEAE leading to discontinuation 0 (0.0) 3 (33.3) 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 4 (8.0)
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1b (16.7) 1 (2.0)
TEAEs in $3 patients in any treatment group
Hypertension 1 (14.3) 2 (22.2) 2 (16.7) 0 (0.0) 2 (22.2) 2 (33.3) 9 (18.0)
Muscle spasms 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3) 3 (33.3) 2 (33.3) 6 (12.0)
Arteriovenous fistula site complication 2 (28.6) 0 (0.0) 0 (0.0) 2 (28.6) 1 (11.1) 0 (0.0) 5 (10.0)
Headache 0 (0.0) 1 (11.1) 1 (8.3) 0 (0.0) 0 (0.0) 3 (50.0) 5 (10.0)
Influenza 1 (14.3) 1 (11.1) 0 (0.0) 1 (14.3) 0 (0.0) 2 (33.3) 5 (10.0)
Epistaxis 1 (14.3) 2 (22.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.0)
Hematuria 2 (28.6) 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.0)
Nausea 0 (0.0) 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 3 (6.0)
Urinary tract infection 2 (28.6) 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.0)
TEAE, treatment-emergent adverse event.
aIn REN-001, 2 deaths occurred in the placebo group. A 53-year-old male died on day 186 of coronary artery disease, and a 76-year-old female died on day 148 of cardiomyopathy. Both
patients had a history of cardiovascular disease.
bIn REN-002, a 70-year-old male died in the s.c. sotatercept 0.4‒0.5 mg/kg group on day 132, of cardiac failure. The patient had a history of cardiovascular disease and the event was not
considered related to study treatment.
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effects on total hip or lumbar spine BMD were
apparent. Mixed findings in the assessed skeletal end-
points indicate that sotatercept’s effects on bone vol-
ume in the CKD-MBD setting are not fully understood.
Furthermore, despite recent progress, BMD is not a
well-established marker of bone disease in patients
with ESKD.
Sotatercept showed a dose-dependent trend to-
ward slowing progression of abdominal aortic
vascular calcification. The highest mean percentage
increase from baseline in Agatston score (48.6%) was
observed with placebo; the smallest (7.6%) was
observed with sotatercept 0.7 mg/kg. Similar results
were observed for volumetric score and square root
of volumetric score.
REN-001 parameters measured to determine sota-
tercept’s pharmacodynamic effects (e.g., Hb, BMD,
Agatston score) generally showed dose-dependency
when it was administered monthly (0.3‒0.7 mg/kg).
Paradoxically, this effect was lost when sotatercept was
administered with higher and/or more frequent doses
(every 2 weeks). A ligand and receptor pair within the
TGF-b superfamily can have opposing effects,
depending on the tissue and biologic context.25
Therefore, it is plausible that opposing effects could
be observed when the ActRIIA receptor is highly
presented with sotatercept administration, possibly by
changing the relative inhibition of various ligands in
the circulation or at the tissue level (e.g., changing
their signaling profile through various native TGF-b
superfamily receptors).
Interpretation of our findings is limited by the small
number of patients in each dose group, differences in
baseline characteristics, unmeasured variables (e.g.,
dialysate calcium), relatively short treatment duration,
and background co-medication patterns. Patient selec-
tion criteria were based on presence of ESA-responsive
anemia, not CKD-MBD. Selected sotatercept dose levels
were based on Hb dynamics and its predicted effects on
Hb. Overall, our findings may have been influenced by
high variability, curtailing our ability to detect
“signal” versus “noise.”
In summary, although highly preliminary and
derived from a small number of patients, current
vascular and bone findings with sotatercept treatment,
along with preclinical findings of activin’s role in
vascular and bone changes and RAP-011 in decreasing
vascular calcification in CKD,19–21 suggest that target-
ing ActRIIA activity may be valuable in slowing
vascular disease progression in CKD patients. We
believe that these highly preliminary data hold promise
for modulating activin biology in CKD. Further pre-
clinical and clinical studies targeting ActRIIA activity
in CKD may be warranted.
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